Ph. D. Project
Research of new therapeutic targets in pancreatic ductal adenocarcinoma.
2020/04/15 - 2022/11/30
Pancreatic cancer is the seventh leading cause of cancer-related death worldwide with a very poor prognosis and a 5-year survival
rate of 9% in 2019. Pancreatic ductal adenocarcinomas (PDAC) occurring in exocrine glands represent 85% of diagnosed cases. Most
of treatment are ineffective and molecular mechanisms of PDAC are complex, making this disease difficult to cure. Molecular
mechanisms at the beginning of initiation and progression of PDAC have recently been described. Identification of new molecular
targets in PDAC may improve both efficiency of treatments and overall survival of patients.
This PhD will focus on the identification of new molecular targets for the treatment of PDAC and will focus on the interest of the
DNA Damage Protein 2 (DDB2), especially its role in cell proliferation, participation in EMT, migration and associated signalling
pancreatic cancer, genomic, DDB2
Biology, Signals and Systems in Cancer and Neuroscience